Related Experiment Videos
Assessment of palliative chemotherapy: a step beyond response
D J Dodwell1, A J Rathmell, D V Ash
1Yorkshire Regional Centre for Cancer Treatment, Cookridge Hospital, Leeds, UK.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|January 1, 1993
Abstract:
In summary, tumour response is a useful index of cytotoxic activity, but is of limited value in the assessment of benefit to the patient following treatment with cytotoxic drugs. Survival is a similarly inappropriate endpoint to assess the clinical benefits of palliative cytotoxic therapy. The widespread introduction of QL assessment as a primary outcome measure in cancer therapy will enhance our understanding of the value of a wide range of established cancer treatments, not only that of palliative chemotherapy, but also surgery and radiotherapy.